A narrative review pulls together 25 years of work on lithium as a disease-modifying agent in mild cognitive impairment and Alzheimer's disease. The mechanistic case is broad rather than targeted: induction of Bcl-2, enhanced BDNF signalling, GSK-3β inhibition, mitochondrial stabilisation and reduced oxidative stress. In people, spectroscopy studies found raised N-acetylaspartate and structural MRI found preserved grey matter in hippocampal and corticolimbic regions.
The dose is the interesting part. Concentrations around 0.3 mM — well below the 0.6 to 1.0 mM used in bipolar disorder — carried neurotrophic effects in preclinical models. Epidemiological work has linked cumulative lithium exposure with lower dementia risk, and early randomised trials in mild cognitive impairment suggested cognitive stabilisation and favourable tau biomarkers at doses that were well tolerated. The authors propose a prospective trial of low-dose lithium orotate, and note the renal and thyroid risks that made higher-dose carbonate unattractive for this indication.
So the correct action today is none, beyond being ready for the question. Patients and families read about this, and lithium's reputation among general physicians in India is poor enough that the conversation tends to end badly. It is worth being able to say clearly: biologically plausible, epidemiologically suggestive, no completed definitive trial, and not something to start outside one.
- Be ready for the patient or family question — the mechanism story is persuasive and widely reported
- Do not initiate lithium for cognitive indications outside a trial
- In patients already on lithium for bipolar disorder, this changes nothing about monitoring
- Keep checking renal and thyroid function on standard schedules regardless of dose
- If low-dose lithium is ever established, cost and availability would make it unusually relevant to Indian practice
Why it matters
The cheapest plausible disease-modifying candidate in dementia is a drug psychiatrists already know how to monitor.
Don't overread it
This is a narrative review of mechanism, imaging and epidemiology — the human trial evidence is early and the repletion hypothesis is unreplicated.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for psychiatry, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free